Buy These 3 Beaten-Down MedTech Stocks for a Turnaround Soon

Market Overview - Investors' optimism has driven the market to record highs following the U.S. Federal Reserve's policy update, which confirmed rate cut expectations in 2024, but a bearish outlook is maintained by some strategists warning of a potential downturn [1][11] - Geopolitical turmoil, including the Israel-Hamas conflict, the Russia-Ukraine war, and tensions between China and Taiwan, has led to rising raw material costs and supply-chain disruptions, causing margin pressure for many companies [2] Company Analysis Option Care Health (OPCH) - Option Care Health has a Zacks Rank of 2 (Buy) and a Value Score of B, with a forward 12-month Price/Sales ratio of 1.02, lower than its median of 1.14 and significantly discounted compared to the S&P 500's 3.99 [6][10] - The company has shown resilience post-cybersecurity incident, maintaining a patient satisfaction rate of 93% and a Net Promoter Score of 76.2, while focusing on operational excellence and growth [5][14] - OPCH's earnings yield is 4.01%, with projected earnings growth of 15.71% for 2025 [16] Lantheus (LNTH) - Lantheus holds a Zacks Rank of 2 and a Value Score of A, with a forward 12-month Price/Sales ratio of 3.72, compared to its median of 3.42 and discounted against the S&P 500's 3.99 [18] - The company is focused on operational excellence and innovation, particularly with its PYLARIFY imaging agent for prostate cancer, which is projected to generate sales of nearly $1 billion this year [7][8] - Lantheus has an earnings yield of 8.72% and anticipates earnings growth of 14.13% for 2024 [8] Hologic (HOLX) - Hologic also has a Zacks Rank of 2 and a Value Score of B, with a forward 12-month Price/Sales ratio of 4.18, lower than its median of 4.31 and discounted compared to the S&P 500's 3.99 [10] - The company has expanded its product offerings significantly, with a 40% growth in its international business since 2019, and has over $2 billion in cash to fund initiatives and acquisitions [9][19] - Hologic's earnings yield is 5.47%, with projected earnings growth of 3.03% for fiscal 2024 [20]